fig1

The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas

Figure 1. Graphical abstract illustrating the targets of interest described. mAB: Monoclonal antibody; TKI: tyrosine kinase inhibitor; msln: mesothelin; ADC: antibody-drug conjugate.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/